Champions Oncology Inc
NASDAQ:CSBR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Champions Oncology Inc
NASDAQ:CSBR
|
US |
|
C
|
Citrix Systems Inc
XETRA:CTX
|
US |
Champions Oncology Inc
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Baltimore, Maryland and currently employs 194 full-time employees. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Baltimore, Maryland and currently employs 194 full-time employees. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
Operational performance: Services revenue hit a record, and Champions delivered its third consecutive quarter of positive adjusted EBITDA ($575,000) despite overall revenue being slightly down year-over-year.
Revenue mix: Total revenue was $16.6 million, down ~3% from $17.0 million a year ago, driven by no data revenue this quarter versus $4.5 million in the prior-year period; core study revenue was $16.6 million, up ~32% year‑over‑year.
Data momentum: Management closed a 6‑figure data deal in the quarter (expected to be recognized in Q4) and expects incremental revenue in Q4 from a previously announced large data contract.
Margins & cost drivers: Gross margin fell to 47% from 61% a year ago, with $8.8 million cost of sales (vs $6.6 million) and >$2 million of outsourced lab/radiolabeling costs that management expects to reduce as work is brought in‑house.
Cash & balance sheet: Ended the quarter with $7.1 million in cash, no debt, and used $1.4 million in operating cash during the quarter.
Investments & subsidiary update: Champions is continuing to invest in its data platform and its discovery subsidiary (Corellia), expects to include Corellia funding in fiscal 2027 budget assumptions, and is pursuing external financing for Corellia.
Outlook & cadence: Management reiterated company-level goals of full‑year revenue growth and full‑year positive adjusted EBITDA, expects payoffs from investments to begin in fiscal 2027 with stronger acceleration in fiscal 2028.
